<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:us-roles="http://fasb.org/us-roles/2020-01-31" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:gild="http://gilead.com/20200930">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_029_US%2DGAAP%2D2020 -->
<!-- Field: Set; Name: xdx; ID: xdx_035_gild_gilead.com_20200930 -->
<!-- Field: Set; Name: xdx; ID: xdx_042_20200930_20200930 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DEntityCentralIndexKey_0000882095 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
  <ix:hidden>
    <ix:nonNumeric contextRef="From2020-09-30to2020-09-30" name="dei:EntityCentralIndexKey">0000882095</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2020-09-30to2020-09-30" format="ixt:booleanfalse" name="dei:AmendmentFlag">false</ix:nonNumeric>
    </ix:hidden>
  <ix:references>
    <link:schemaRef xlink:href="gild-20200930.xsd" xlink:type="simple" />
    </ix:references>
  <ix:resources>
    <xbrli:context id="From2020-09-30to2020-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-09-30</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    </ix:resources>
  </ix:header>
</div>


<p style="margin: 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="margin: 0"></p>

<p style="margin: 0"></p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 14pt"><b>UNITED
STATES</b></span></p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 14pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Washington, D.C. 20549</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="margin-left: auto; margin-right: auto; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-decoration: none; font-size: 14pt"><b>FORM
<span id="xdx_904_edei--DocumentType_c20200930__20200930_zWBbKWCTZHO5"><ix:nonNumeric contextRef="From2020-09-30to2020-09-30" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Current Report</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Pursuant to Section 13 or 15(d)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>of the
Securities Exchange Act of 1934</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Date of Report (Date of Earliest
Event Reported): <span id="xdx_902_edei--DocumentPeriodEndDate_c20200930__20200930_zKpgWAzwOAVb"><ix:nonNumeric contextRef="From2020-09-30to2020-09-30" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">September 30, 2020</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<!-- Field: Rule-Page --><div style="margin-left: auto; margin-right: auto; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 20pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="xdx_90D_edei--EntityRegistrantName_c20200930__20200930_zBahphUh2lw"><b><ix:nonNumeric contextRef="From2020-09-30to2020-09-30" name="dei:EntityRegistrantName">Gilead
Sciences, Inc.</ix:nonNumeric></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Exact Name of Registrant as Specified in its Charter)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="white-space: nowrap; width: 34%; font-size: 10pt; text-align: center"><b><span id="xdx_905_edei--EntityIncorporationStateCountryCode_c20200930__20200930_zWTwdpKrHO94"><ix:nonNumeric contextRef="From2020-09-30to2020-09-30" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b><br />
    <b>(State or Other <br />
    Jurisdiction<br />
    of Incorporation)</b></td>
    <td style="width: 32%; font-size: 10pt; text-align: center"><b><span id="xdx_900_edei--EntityFileNumber_c20200930__20200930_zKdawpkWec14"><ix:nonNumeric contextRef="From2020-09-30to2020-09-30" name="dei:EntityFileNumber">0-19731</ix:nonNumeric></span></b><br />
    <b>(Commission File Number)</b></td>
    <td style="white-space: nowrap; width: 34%">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_907_edei--EntityTaxIdentificationNumber_c20200930__20200930_ze34kR0uOXK8"><ix:nonNumeric contextRef="From2020-09-30to2020-09-30" name="dei:EntityTaxIdentificationNumber">94-3047598</ix:nonNumeric></span></b><br />
        <b>(I.R.S. Employer</b></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Identification No.)</b></p></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 50%"><b><span id="xdx_905_edei--EntityAddressAddressLine1_c20200930__20200930_zuyCMREHW4Bi" style="font-size: 10pt"><ix:nonNumeric contextRef="From2020-09-30to2020-09-30" name="dei:EntityAddressAddressLine1">333
    Lakeside Drive</ix:nonNumeric></span></b><br />
<b><span style="font-size: 10pt"> <span id="xdx_900_edei--EntityAddressCityOrTown_c20200930__20200930_zSoaiukRH9t3"><ix:nonNumeric contextRef="From2020-09-30to2020-09-30" name="dei:EntityAddressCityOrTown">Foster
    City</ix:nonNumeric></span></span></b><b><span style="font-size: 10pt">, <span id="xdx_903_edei--EntityAddressStateOrProvince_c20200930__20200930_zo0JhxIsuF0e"><ix:nonNumeric contextRef="From2020-09-30to2020-09-30" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince">California</ix:nonNumeric></span></span></b></td>
    <td style="text-align: center; width: 50%"><b><span id="xdx_90D_edei--EntityAddressPostalZipCode_c20200930__20200930_zXP6JkyuYmX7" style="font-size: 10pt"><ix:nonNumeric contextRef="From2020-09-30to2020-09-30" name="dei:EntityAddressPostalZipCode">94404</ix:nonNumeric></span></b></td></tr>
<tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt"><b>(Address of Principal
    Executive Offices)</b></span></td>
    <td style="text-align: center"><span style="font-size: 10pt"><b>(Zip Code)</b></span></td></tr>
</table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Registrant&#8217;s telephone number,
including area code: (<span id="xdx_90B_edei--CityAreaCode_c20200930__20200930_z3h6WatUJwpb"><ix:nonNumeric contextRef="From2020-09-30to2020-09-30" name="dei:CityAreaCode">650</ix:nonNumeric></span></b><b>) <span id="xdx_902_edei--LocalPhoneNumber_c20200930__20200930_z5IrcReX5L4l"><ix:nonNumeric contextRef="From2020-09-30to2020-09-30" name="dei:LocalPhoneNumber">574-3000</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><b>Not Applicable</b><br />
<b>(Former Name or Former Address, if Changed Since Last Report)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="text-align: center; width: 0.5in"><span style="font-family: Wingdings"><span id="xdx_904_edei--WrittenCommunications_c20200930__20200930_zgZvc5ZfLMhj"><ix:nonNumeric contextRef="From2020-09-30to2020-09-30" format="ixt:booleanfalse" name="dei:WrittenCommunications">&#168;</ix:nonNumeric></span></span></td><td style="text-align: justify">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</td></tr>                                                                                                                                                                                                                                                                                                       <tr style="vertical-align: top">
<td style="text-align: center">&#160;</td><td style="text-align: justify">&#160;</td></tr>
</table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="text-align: center; width: 0.5in"><span style="font-family: Wingdings"><span id="xdx_90E_edei--SolicitingMaterial_c20200930__20200930_zhR3mtD3ULze"><ix:nonNumeric contextRef="From2020-09-30to2020-09-30" format="ixt:booleanfalse" name="dei:SolicitingMaterial">&#168;</ix:nonNumeric></span></span></td><td style="text-align: justify">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</td></tr>                                                                                                                                                                                                                                                                                                     <tr style="vertical-align: top">
<td>&#160;</td><td style="text-align: justify">&#160;</td></tr>
</table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="text-align: center; width: 0.5in"><span style="font-family: Wingdings"><span id="xdx_900_edei--PreCommencementTenderOffer_c20200930__20200930_zHRMaIgSqYHh"><ix:nonNumeric contextRef="From2020-09-30to2020-09-30" format="ixt:booleanfalse" name="dei:PreCommencementTenderOffer">&#168;</ix:nonNumeric></span></span>&#160;<span style="font-family: Wingdings"></span></td><td style="text-align: justify">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</td></tr>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 <tr style="vertical-align: top">
<td>&#160;</td><td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
<td style="text-align: center"><span style="font-family: Wingdings"><span id="xdx_907_edei--PreCommencementIssuerTenderOffer_c20200930__20200930_zELLuuKjDi8"><ix:nonNumeric contextRef="From2020-09-30to2020-09-30" format="ixt:booleanfalse" name="dei:PreCommencementIssuerTenderOffer">&#168;</ix:nonNumeric></span></span></td><td style="text-align: justify">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Securities registered pursuant to Section 12(b)
of the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="border-bottom: Black 1pt solid; padding-top: 2pt; padding-right: 2pt; padding-left: 2pt; width: 33%; text-align: center; vertical-align: bottom"><b>Title
    of Each Class</b></td>
    <td style="padding-bottom: 1pt; width: 1%"><b>&#160;</b></td>
    <td style="border-bottom: Black 1pt solid; padding-top: 2pt; padding-right: 2pt; padding-left: 2pt; width: 32%; text-align: center; vertical-align: bottom"><b>Trading
    Symbol(s)</b></td>
    <td style="padding-bottom: 1pt; width: 1%"><b>&#160;</b></td>
    <td style="border-bottom: Black 1pt solid; padding-top: 2pt; padding-right: 2pt; padding-left: 2pt; width: 33%; text-align: center; vertical-align: bottom"><b>Name
    of Each Exchange on which<br />
    Registered</b></td></tr>
<tr style="vertical-align: top">
    <td style="padding: 2pt; text-align: center"><span id="xdx_902_edei--Security12bTitle_c20200930__20200930_zDwprQ8Amitk"><ix:nonNumeric contextRef="From2020-09-30to2020-09-30" name="dei:Security12bTitle">Common Stock, par value $0.001 per share</ix:nonNumeric></span></td>
    <td>&#160;</td>
    <td style="padding: 2pt; text-align: center"><span id="xdx_90A_edei--TradingSymbol_c20200930__20200930_zdrZYRJx5mUl"><ix:nonNumeric contextRef="From2020-09-30to2020-09-30" name="dei:TradingSymbol">GILD</ix:nonNumeric></span></td>
    <td>&#160;</td>
    <td style="padding: 2pt; text-align: center"><span id="xdx_904_edei--SecurityExchangeName_c20200930__20200930_zdAvw6b0Nur"><ix:nonNumeric contextRef="From2020-09-30to2020-09-30" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">The Nasdaq Global Select Market</ix:nonNumeric></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of
1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Emerging growth company&#160;&#160;<span style="font-family: Times New Roman, Times, Serif"><span style="font-family: Wingdings"><span id="xdx_90D_edei--EntityEmergingGrowthCompany_c20200930__20200930_zoUVQsKVxne9"><ix:nonNumeric contextRef="From2020-09-30to2020-09-30" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#168;</ix:nonNumeric></span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#160;<span style="font-family: Times New Roman, Times, Serif"><span style="font-family: Wingdings">&#168;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0; margin-bottom: 0; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Item 1.01. Entry into a Material Definitive Agreement.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Supplemental Indenture</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">On September 30, 2020, Gilead Sciences,
Inc. (the &#8220;Company&#8221;) and Wells Fargo Bank, National Association, as trustee (the &#8220;Trustee&#8221; and, together
with the Company, the &#8220;Parties&#8221;), entered into an Eighth Supplemental Indenture (the &#8220;Eighth Supplemental Indenture&#8221;)
to the Indenture between the Parties, dated as of March 30, 2011 (the &#8220;Base Indenture&#8221;). The Eighth Supplemental Indenture
relates to the Company&#8217;s issuance of (a) $500,000,000 aggregate principal amount of the Company&#8217;s Floating Rate Notes
due 2021 (the &#8220;2021 Floating Rate Notes&#8221;), (b) $500,000,000 aggregate principal amount of the Company&#8217;s Floating
Rate Notes due 2023 (the &#8220;2023 Floating Rate Notes&#8221; and together with the 2021 Floating Rate Notes, the &#8220;Floating
Rate Notes&#8221;), (c) $2,000,000,000 aggregate principal amount of the Company&#8217;s 0.750% Senior Notes due 2023 (the &#8220;2023
Fixed Rate Notes&#8221;), (d) $750,000,000 aggregate principal amount of the Company&#8217;s 1.200% Senior Notes due 2027 (the
&#8220;2027 Fixed Rate Notes&#8221;), (e) $1,000,000,000 aggregate principal amount of the Company&#8217;s 1.650% Senior Notes
due 2030 (the &#8220;2030 Fixed Rate Notes&#8221;), (f) $1,000,000,000 aggregate principal amount of the Company&#8217;s 2.600%
Senior Notes due 2040 (the &#8220;2040 Fixed Rate Notes&#8221;), and (g) $1,500,000,000 aggregate principal amount of the Company&#8217;s
2.800% Senior Notes due 2050 (the &#8220;2050 Fixed Rate Notes&#8221; and, together with the 2023 Fixed Rate Notes, 2027 Fixed
Rate Notes, the 2030 Fixed Rate Notes and the 2040 Fixed Rate Notes, the &#8220;Fixed Rate Notes&#8221; and, collectively the Fixed
Rate Notes together with the Floating Rate Notes, the &#8220;Notes&#8221;). The Notes were sold in a public offering pursuant to
the Company&#8217;s Registration Statement on Form S-3 (File No. 333-242321).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The 2023 Fixed Rate Notes will pay interest
semi-annually at a rate of 0.750% per annum until September 29, 2023. The 2027 Fixed Rate Notes will pay interest semi-annually
at a rate of 1.200% per annum until October 1, 2027. The 2030 Fixed Rate Notes will pay interest semi-annually at a rate of 1.650%
per annum until October 1, 2030. The 2040 Fixed Rate Notes will pay interest semi-annually at a rate of 2.600% per annum until
October 1, 2040. The 2050 Fixed Rate Notes will pay interest semi-annually at a rate of 2.800% per annum until October 1, 2050.
The 2021 Floating Rate Notes will pay interest each March 17, June 17, September 17 and December 17 until September 17, 2021. The
2023 Floating Rate Notes will pay interest each March 29, June 29, September 29 and December 29 until September 29, 2023. The interest
rate for the Floating Rate Notes for each interest period will be the Benchmark <span style="background-color: white">(as defined
in the Supplemental Indenture) </span>as determined on the applicable Reference Time (as defined in the Supplemental Indenture),
plus 0.15% with respect to the 2021 Floating Rate Notes and 0.52% with respect to the 2023 Floating Rate Notes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company intends to use the net proceeds
from the sale of the Floating Rate Notes, the 2023 <span style="background-color: white">Fixed Rate Notes, the </span>2030 <span style="background-color: white">Fixed
Rate Notes and the </span>2040 <span style="background-color: white">Fixed Rate Notes</span>, together with other sources of liquidity,
to finance the cash consideration payable in connection with the Company&#8217;s previously announced acquisition (the &#8220;Acquisition&#8221;)
of Immunomedics, Inc., a Delaware corporation (&#8220;Immunomedics&#8221;), pursuant to the Agreement and Plan of Merger, dated
September 13, 2020, among Immunomedics, the Company and Maui Merger Sub, Inc., a Delaware corporation (the &#8220;Merger Agreement&#8221;),
and to pay related fees and expenses. The Company intends to use the net proceeds from the offering of the 2027 Fixed Rate Notes
and the 2050 Fixed Rate Notes to repay $1,000,000,000 in aggregate principal amount of its 4.50% Senior Notes due 2021 and $1,250,000,000
in aggregate principal amount of its 4.40% Senior Notes due 2021. Pending that application of funds, the Company intends to invest
the net proceeds from this offering in United States government obligations, bank deposits or other secure, short-term investments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Base Indenture and the Eighth Supplemental
Indenture contain certain restrictions, including a limitation that restricts the Company&#8217;s ability and ability of certain
of its subsidiaries to create or incur secured indebtedness, enter into sale and leaseback transactions and consolidate, merge
or transfer all or substantially all of the Company&#8217;s assets and the assets of its subsidiaries, and also requires the Company
to offer to repurchase the Notes upon certain change of control events.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company may redeem some or all of the
Fixed Rate Notes at any time and from time to time at the applicable redemption prices described in the form of such notes. The
Company will not have the option to redeem (i) the 2021 Floating Rate Notes, in whole or in part, prior to the maturity date or
(ii) the 2023 Floating Rate Notes, in whole or in part, prior to the applicable par call date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In the event that (a) the Acquisition
is not consummated on or before September 13, 2021, or (b) if prior to such date, the Merger Agreement is terminated, the Company
will be obligated to redeem the Floating Rate Notes, the 2023 <span style="background-color: white">Fixed Rate Notes, the </span>2030
<span style="background-color: white">Fixed Rate Notes and the </span>2040 <span style="background-color: white">Fixed Rate Notes
</span>at a special mandatory redemption price equal to 101% of the aggregate principal amount of such Notes, plus accrued and
unpaid interest to, but excluding, the special mandatory redemption date described in the Eighth Supplemental Indenture.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin: 0pt 0">For a complete description of the terms and conditions of the
Base Indenture, please refer to the Base Indenture, filed as <a href="http://www.sec.gov/Archives/edgar/data/882095/000119312511086814/dex41.htm" style="-sec-extract: exhibit">Exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K, filed with the Commission on April 1, 2011</a> and incorporated herein by reference. For a complete description of the terms and conditions
of the Eighth Supplemental Indenture and the Notes, please refer to the Eighth Supplemental Indenture and the forms of each series
of Notes, each of which is incorporated herein by reference and attached to this Current Report on Form 8-K as Exhibits 4.1, 4.2,
4.3, 4.4, 4.5, 4.6, 4.7 and 4.8, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 2.03. Creation of a Direct Financial Obligation or an
Obligation under an Off-Balance Sheet Arrangement of a Registrant.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The information set forth in Item 1.01
is incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25pt">Item 9.01. Financial Statements and Exhibits.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;Exhibits.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following exhibits are filed as part of this Current Report
on Form 8-K:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; padding: 0.25pt 0.25pt 0.5pt; width: 10%; font-size: 10pt"><span style="font-size: 10pt"><b>Exhibit<br />
 Number</b></span></td>
    <td style="padding: 0.25pt; width: 2%">&#160;</td>
    <td style="border-bottom: black 1pt solid; padding: 0.25pt 0.25pt 0.5pt; width: 88%; font-size: 10pt; text-align: center"><span style="font-size: 10pt"><b>Description</b></span></td></tr>
<tr>
    <td style="padding: 0.25pt; vertical-align: top; font-size: 10pt"><a href="tm2031940d2_ex4-1.htm" style="-sec-extract: exhibit">4.1</a></td>
    <td style="padding: 0.25pt; vertical-align: bottom">&#160;</td>
    <td style="padding: 0.25pt; vertical-align: top; font-size: 10pt"><a href="tm2031940d2_ex4-1.htm" style="-sec-extract: exhibit">Eighth Supplemental Indenture, dated as of September 30, 2020, between the Company and Wells Fargo Bank, National Association, as Trustee</a></td></tr>
<tr>
    <td style="padding: 0.25pt; vertical-align: top">&#160;</td>
    <td style="padding: 0.25pt; vertical-align: bottom">&#160;</td>
    <td style="padding: 0.25pt; vertical-align: top">&#160;</td></tr>
<tr>
    <td style="padding: 0.25pt; vertical-align: top; font-size: 10pt"><a href="tm2031940d2_ex4-1.htm" style="-sec-extract: exhibit">4.2</a></td>
    <td style="padding: 0.25pt; vertical-align: bottom">&#160;</td>
    <td style="padding: 0.25pt; vertical-align: top; font-size: 10pt"><a href="tm2031940d2_ex4-1.htm" style="-sec-extract: exhibit">Form of 2021 Floating Rate Note (included in Exhibit 4.1 above)</a></td></tr>
<tr>
    <td style="padding: 0.25pt; vertical-align: top">&#160;</td>
    <td style="padding: 0.25pt; vertical-align: bottom">&#160;</td>
    <td style="padding: 0.25pt; vertical-align: top">&#160;</td></tr>
<tr>
    <td style="padding: 0.25pt; vertical-align: top; font-size: 10pt"><a href="tm2031940d2_ex4-1.htm" style="-sec-extract: exhibit">4.3</a></td>
    <td style="padding: 0.25pt; vertical-align: bottom">&#160;</td>
    <td style="padding: 0.25pt; vertical-align: top; font-size: 10pt"><a href="tm2031940d2_ex4-1.htm" style="-sec-extract: exhibit">Form of 2023 Floating Rate Note (included in Exhibit 4.1 above)</a></td></tr>
<tr>
    <td style="padding: 0.25pt; vertical-align: top">&#160;</td>
    <td style="padding: 0.25pt; vertical-align: bottom">&#160;</td>
    <td style="padding: 0.25pt; vertical-align: top">&#160;</td></tr>
<tr>
    <td style="padding: 0.25pt; vertical-align: top; font-size: 10pt"><a href="tm2031940d2_ex4-1.htm" style="-sec-extract: exhibit">4.4</a></td>
    <td style="padding: 0.25pt; vertical-align: bottom">&#160;</td>
    <td style="padding: 0.25pt; vertical-align: top; font-size: 10pt"><a href="tm2031940d2_ex4-1.htm" style="-sec-extract: exhibit">Form of 2023 Fixed Rate Note (included in Exhibit 4.1 above)</a></td></tr>
<tr>
    <td style="padding: 0.25pt; vertical-align: top">&#160;</td>
    <td style="padding: 0.25pt; vertical-align: bottom">&#160;</td>
    <td style="padding: 0.25pt; vertical-align: top">&#160;</td></tr>
<tr>
    <td style="padding: 0.25pt; vertical-align: top; font-size: 10pt"><a href="tm2031940d2_ex4-1.htm" style="-sec-extract: exhibit">4.5</a></td>
    <td style="padding: 0.25pt; vertical-align: bottom">&#160;</td>
    <td style="padding: 0.25pt; vertical-align: top; font-size: 10pt"><a href="tm2031940d2_ex4-1.htm" style="-sec-extract: exhibit">Form of 2027 Fixed Rate Note (included in Exhibit 4.1 above)</a></td></tr>
<tr>
    <td style="padding: 0.25pt; vertical-align: top; font-size: 10pt">&#160;</td>
    <td style="padding: 0.25pt; vertical-align: bottom; font-size: 10pt">&#160;</td>
    <td style="padding: 0.25pt; vertical-align: top; font-size: 10pt">&#160;</td></tr>
<tr>
    <td style="padding: 0.25pt; vertical-align: top; font-size: 10pt"><a href="tm2031940d2_ex4-1.htm" style="-sec-extract: exhibit">4.6</a></td>
    <td style="padding: 0.25pt; vertical-align: bottom; font-size: 10pt">&#160;</td>
    <td style="padding: 0.25pt; vertical-align: top; font-size: 10pt"><a href="tm2031940d2_ex4-1.htm" style="-sec-extract: exhibit">Form of 2030 Fixed Rate Note (included in Exhibit 4.1 above)</a></td></tr>
<tr>
    <td style="padding: 0.25pt; vertical-align: top; font-size: 10pt">&#160;</td>
    <td style="padding: 0.25pt; vertical-align: bottom; font-size: 10pt">&#160;</td>
    <td style="padding: 0.25pt; vertical-align: top; font-size: 10pt">&#160;</td></tr>
<tr>
    <td style="padding: 0.25pt; vertical-align: top; font-size: 10pt"><a href="tm2031940d2_ex4-1.htm" style="-sec-extract: exhibit">4.7</a></td>
    <td style="padding: 0.25pt; vertical-align: bottom; font-size: 10pt">&#160;</td>
    <td style="padding: 0.25pt; vertical-align: top; font-size: 10pt"><a href="tm2031940d2_ex4-1.htm" style="-sec-extract: exhibit">Form of 2040 Fixed Rate Note (included in Exhibit 4.1 above)</a></td></tr>
<tr>
    <td style="padding: 0.25pt; vertical-align: top; font-size: 10pt">&#160;</td>
    <td style="padding: 0.25pt; vertical-align: bottom; font-size: 10pt">&#160;</td>
    <td style="padding: 0.25pt; vertical-align: top; font-size: 10pt">&#160;</td></tr>
<tr>
    <td style="padding: 0.25pt; vertical-align: top; font-size: 10pt"><a href="tm2031940d2_ex4-1.htm" style="-sec-extract: exhibit">4.8</a></td>
    <td style="padding: 0.25pt; vertical-align: bottom; font-size: 10pt">&#160;</td>
    <td style="padding: 0.25pt; vertical-align: top; font-size: 10pt"><a href="tm2031940d2_ex4-1.htm" style="-sec-extract: exhibit">Form of 2050 Fixed Rate Note (included in Exhibit 4.1 above)</a></td></tr>
<tr>
    <td style="padding: 0.25pt; vertical-align: top">&#160;</td>
    <td style="padding: 0.25pt; vertical-align: bottom">&#160;</td>
    <td style="padding: 0.25pt; vertical-align: top">&#160;</td></tr>
<tr>
    <td style="padding: 0.25pt; vertical-align: top; font-size: 10pt"><a href="tm2031940d2_ex5-1.htm" style="-sec-extract: exhibit">5.1</a></td>
    <td style="padding: 0.25pt; vertical-align: bottom">&#160;</td>
    <td style="padding: 0.25pt; vertical-align: top; font-size: 10pt"><a href="tm2031940d2_ex5-1.htm" style="-sec-extract: exhibit">Opinion of Davis Polk &amp; Wardwell LLP regarding the validity of the Notes</a></td></tr>
<tr>
    <td style="padding: 0.25pt; vertical-align: top">&#160;</td>
    <td style="padding: 0.25pt; vertical-align: bottom">&#160;</td>
    <td style="padding: 0.25pt; vertical-align: top">&#160;</td></tr>
<tr>
    <td style="padding: 0.25pt; vertical-align: top; font-size: 10pt"><a href="tm2031940d2_ex5-1.htm" style="-sec-extract: exhibit">23.1</a></td>
    <td style="padding: 0.25pt; vertical-align: bottom">&#160;</td>
    <td style="padding: 0.25pt; vertical-align: top; font-size: 10pt"><a href="tm2031940d2_ex5-1.htm" style="-sec-extract: exhibit">Consent of Davis Polk &amp; Wardwell LLP (included as part of Exhibit 5.1)</a></td></tr>
<tr>
    <td style="padding: 0.25pt; vertical-align: top; font-size: 10pt">&#160;</td>
    <td style="padding: 0.25pt; vertical-align: bottom; font-size: 10pt">&#160;</td>
    <td style="padding: 0.25pt; vertical-align: top; font-size: 10pt">&#160;</td></tr>
<tr>
    <td style="padding: 0.25pt; vertical-align: top; font-size: 10pt">104</td>
    <td style="padding: 0.25pt; vertical-align: bottom; font-size: 10pt">&#160;</td>
    <td style="padding: 0.25pt; vertical-align: top; font-size: 10pt">Cover Page Interactive Data File (embedded within the Inline XBRL document)</td></tr>
</table>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SIGNATURE</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: top; text-align: left">
    <td>&#160;</td>
    <td colspan="3">GILEAD SCIENCES, INC.</td></tr>
<tr style="vertical-align: top; text-align: left">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td></tr>
<tr style="vertical-align: top; text-align: left">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid">/s/ Andrew D. Dickinson</td></tr>
<tr style="vertical-align: top; text-align: left">
    <td style="width: 50%">&#160;</td>
    <td style="width: 5%">&#160;</td>
    <td style="width: 5%">Name:</td>
    <td style="width: 40%">Andrew D. Dickinson</td></tr>
<tr style="vertical-align: top; text-align: left">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>Title:</td>
    <td>Executive Vice President and Chief Financial
Officer</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dated: September 30, 2020</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjV0KwjAQhE/QOyx5LpqWKto3LSpiFSkivka7SrDNlk38O5K3NLaIy8KyzHwzQoRiQXNdIcNhWuSww7qplEMo8IyM5oTekS1XKfhb4EVbx8q49v2BGXkGPTPoyePJC631ri2WKchRP0760RjkMB0kMFmL4KtnZM66ROO0qkCZErZMDWt0il9dwk49yVD9aqv2yFaTSSHqyU5+QyyjGDZ0Vw/iq4U8z0QQthOIBdOt+dbcrKMaZhXWvst26H+DDzhySXg= -->
